GOLD2022

American Society for Experimental Neurotherapeutics Inc

aka ASENT   |   Haddonfield, NJ   |  https://asent.org
GuideStar Charity Check

American Society for Experimental Neurotherapeutics Inc

EIN: 52-2029696


Mission

The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system. ASENT engages in scientific exchanges to encourage contacts between those involved in the discovery and development of neurotherapeutics and to provide opportunities for dialogue between the interested groups. The society organizes education and training and publishes a journal for healthcare practitioners, scientists and officials participating in the neurotherapeutics

Ruling year info

2002

Principal Officer

Jessica Smith

Main address

230 Kings Hwy E Ste. # 245

Haddonfield, NJ 08033 USA

Show more contact info

EIN

52-2029696

Subject area info

Medical education

Neurology

Brain and nervous system disorders

Biotechnology

Genetic research

Show more subject areas

Population served info

Academics

Military personnel

Activists

NTEE code info

Nerve, Muscle and Bone Diseases (G50)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms

Communication

Blog

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

ASENT Annual Meeting

The ASENT Annual Meeting is the premier neurotherapeutics conference where senior leaders from leading payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers in the neurology and neuroscience space gather to ask one question: how can we improve the process of bringing neurotherapeutics to market?

The conference content focuses on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, networking meetings, outstanding pipeline presentations and poster sessions.

Population(s) Served
Academics
Military personnel

Where we work

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

In 2021 ASENT successfully executed our first fully virtual annual meeting to a sold out registration and record breaking attendance.

Financials

American Society for Experimental Neurotherapeutics Inc
Fiscal year: Jan 01 - Dec 31

Revenue vs. expenses:  breakdown

SOURCE: IRS Form 990 info
NET GAIN/LOSS:    in 
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2022 info

SOURCE: IRS Form 990

0.00

Average of 3.34 over 10 years

Months of cash in 2022 info

SOURCE: IRS Form 990

3.6

Average of 6.6 over 10 years

Fringe rate in 2022 info

SOURCE: IRS Form 990

0%

Average of 0% over 10 years

Funding sources info

Source: IRS Form 990

Assets & liabilities info

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990

American Society for Experimental Neurotherapeutics Inc

Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

Fiscal year ending: cloud_download Download Data

American Society for Experimental Neurotherapeutics Inc

Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: cloud_download Download Data

American Society for Experimental Neurotherapeutics Inc

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

This snapshot of American Society for Experimental Neurotherapeutics Inc’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Business model indicators

Profitability info 2018 2019 2020 2021 2022
Unrestricted surplus (deficit) before depreciation $81,610 -$22,551 -$61,709 $33,269 -$193,361
As % of expenses 20.5% -6.6% -16.4% 13.1% -44.9%
Unrestricted surplus (deficit) after depreciation $81,610 -$22,551 -$61,709 $33,269 -$193,361
As % of expenses 20.5% -6.6% -16.4% 13.1% -44.9%
Revenue composition info
Total revenue (unrestricted & restricted) $479,029 $320,803 $313,990 $287,384 $236,991
Total revenue, % change over prior year 13.9% -33.0% -2.1% -8.5% -17.5%
Program services revenue 13.0% 14.3% 8.8% 1.6% 0.7%
Membership dues 8.1% 1.4% 4.5% 6.1% 7.0%
Investment income 0.0% 0.0% 0.0% 0.0% 0.0%
Government grants 0.0% 0.0% 0.0% 0.0% 0.0%
All other grants and contributions 78.9% 84.3% 86.7% 92.3% 92.3%
Other revenue 0.0% 0.0% 0.0% 0.0% 0.0%
Expense composition info
Total expenses before depreciation $397,419 $343,354 $375,701 $254,116 $430,354
Total expenses, % change over prior year -1.5% -13.6% 9.4% -32.4% 69.4%
Personnel 32.4% 39.3% 40.8% 57.2% 42.3%
Professional fees 0.0% 0.0% 0.0% 0.0% 0.0%
Occupancy 0.0% 0.0% 0.0% 0.0% 0.0%
Interest 0.0% 0.0% 0.0% 0.0% 0.0%
Pass-through 0.0% 0.0% 0.0% 0.0% 0.0%
All other expenses 67.6% 60.7% 59.2% 42.8% 57.7%
Full cost components (estimated) info 2018 2019 2020 2021 2022
Total expenses (after depreciation) $397,419 $343,354 $375,701 $254,116 $430,354
One month of savings $33,118 $28,613 $31,308 $21,176 $35,863
Debt principal payment $0 $0 $0 $0 $0
Fixed asset additions $0 $0 $0 $0 $0
Total full costs (estimated) $430,537 $371,967 $407,009 $275,292 $466,217

Capital structure indicators

Liquidity info 2018 2019 2020 2021 2022
Months of cash 5.1 12.2 9.2 15.2 3.6
Months of cash and investments 5.1 12.2 9.2 15.2 3.6
Months of estimated liquid unrestricted net assets 4.9 4.9 2.5 5.3 -2.3
Balance sheet composition info 2018 2019 2020 2021 2022
Cash $167,589 $350,038 $288,329 $321,598 $128,237
Investments $0 $0 $0 $0 $0
Receivables $0 $0 $0 $0 $0
Gross land, buildings, equipment (LBE) $0 $0 $0 $0 $0
Accumulated depreciation (as a % of LBE) 0.0% 0.0% 0.0% 0.0% 0.0%
Liabilities (as a % of assets) 0.0% 0.0% 0.0% 0.0% 0.0%
Unrestricted net assets $163,405 $140,854 $79,145 $112,414 -$80,947
Temporarily restricted net assets $4,184 N/A N/A N/A N/A
Permanently restricted net assets $0 N/A N/A N/A N/A
Total restricted net assets $4,184 $209,184 $209,184 $209,184 $209,184
Total net assets $167,589 $350,038 $288,329 $321,598 $128,237

Key data checks

Key data checks info 2018 2019 2020 2021 2022
Material data errors No No No No No

Operations

The people, governance practices, and partners that make the organization tick.

Documents
Letter of Determination is not available for this organization
Form 1023/1024 is not available for this organization

Principal Officer

Jessica Smith

Number of employees

Source: IRS Form 990

American Society for Experimental Neurotherapeutics Inc

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation
Other
Related
Show data for fiscal year
Compensation data
Download up to 5 most recent years of officer and director compensation data for this organization

There are no highest paid employees recorded for this organization.

American Society for Experimental Neurotherapeutics Inc

Board of directors
as of 05/02/2022
SOURCE: Self-reported by organization
Board of directors data
Download the most recent year of board of directors data for this organization
Board chair

Thomas Sutula, MD, PhD

University of Wisconsin, Madison

Organizational demographics

SOURCE: Self-reported; last updated 7/15/2021

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Female, Not transgender
Sexual orientation
Heterosexual or Straight
Disability status
Person with a disability

Race & ethnicity

No data

Gender identity

No data

Transgender Identity

No data

Sexual orientation

No data

Disability

No data

Contractors

Fiscal year ending
There are no fundraisers recorded for this organization.